Structured evidence table for Vitamin K2 Bone Turnover Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K2 Bone Turnover Randomized Trial | In the Global Burden of Disease 2019 analysis, low bone mineral density was associated with about 438,000 deaths and 166 million disability-adjusted life years, with large increases since 1990 (). | 1 | Zhang Zechen (2025) | The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis |
| Vitamin K2 Bone Turnover Randomized Trial | In a cross-sectional study of 900 Chinese adults, higher ucOC was associated with lower BMD at the spine, femoral neck, and hip, and with higher P1NP and β-CTX, indicating increased turnover (). | 1 | Zhang Zechen (2025) | The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis |
| Vitamin K2 Bone Turnover Randomized Trial | K2 deficiency has been linked to the “calcium paradox,” with insufficient skeletal deposition and increased vascular calcification (). | 1 | Zhang Zechen (2025) | The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis |
| Vitamin K2 Bone Turnover Randomized Trial | It is characterized by low bone mass and deterioration of bone microarchitecture. | 1 | Zhang Zechen (2025) | The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis |
| Vitamin K2 Bone Turnover Randomized Trial | Evidence arises simultaneously from metabolic research, neuroendocrinology, hepatology, reproductive biology, and matrix biochemistry, yet these fields differ substantially in experimental models, assay methodologies, isoform definitions, and clinical endpoints. | 3 | Derwich Wiktor (2026) | Osteocalcin Beyond Bone: Molecular Mechanisms, Endocrine Networks, and Translational Perspectives Across Metabolism, Neurobiology, and Chronic Disease |
| Vitamin K2 Bone Turnover Randomized Trial | This narrative review aims to unify these perspectives by: (a) summarizing structural determinants and carboxylation-dependent isoform biology; (b) outlining receptor-level mechanisms across target organs; (c) consolidating human evidence, including clamp-validated metabolic data; and (d) clarifying methodological and analytical limitations that critically shape the interpretation of OCN physiology. | 3 | Derwich Wiktor (2026) | Osteocalcin Beyond Bone: Molecular Mechanisms, Endocrine Networks, and Translational Perspectives Across Metabolism, Neurobiology, and Chronic Disease |
| Vitamin K2 Bone Turnover Randomized Trial | As this is a narrative review, no formal eligibility criteria, protocol registration, or risk-of-bias tools were applied; studies were selected based on relevance, biological coherence, and their conceptual contribution to OCN physiology. | 3 | Derwich Wiktor (2026) | Osteocalcin Beyond Bone: Molecular Mechanisms, Endocrine Networks, and Translational Perspectives Across Metabolism, Neurobiology, and Chronic Disease |
| Vitamin K2 Bone Turnover Randomized Trial | Bone is increasingly recognized as an endocrine organ, and osteocalcin (OCN) exemplifies this paradigm shift. | 3 | Derwich Wiktor (2026) | Osteocalcin Beyond Bone: Molecular Mechanisms, Endocrine Networks, and Translational Perspectives Across Metabolism, Neurobiology, and Chronic Disease |
Source documents